Adverse reactions associated with nivolumab and small molecule antiangiogenic drugs: A pharmacovigilance analysis
These results can help enhance understanding of the ADRs commonly associated with combination therapy and assist oncologists in formulating screening protocols.
Authors
- Zhaohui Ruan
- Yanan Jia (ORCID: https://orcid.org/0000-0001-6719-6229)
- Lingwa Wang
- Haiyang Li (ORCID: https://orcid.org/0000-0002-9506-0430)
- Ru Wang (ORCID: https://orcid.org/0000-0002-7876-6052)
- Jugao Fang (ORCID: https://orcid.org/0000-0003-1372-7228)
- Yuan Zhang (ORCID: https://orcid.org/0000-0002-7970-6211)
- Yifan Yang (ORCID: https://orcid.org/0009-0003-0588-1812)
Institutions
- Shangrao Normal University (CN)
- Beijing Tongren Hospital (CN)
- Capital Medical University (CN)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1111/bcp.16242
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- National Natural Science Foundation of China
- Beijing Municipal Administration of Hospitals
- Capital Health Research and Development of Special Fund